Effects of a somatostatin analogue SMS 201-995 on hepatic haemodynamics in the pig and on intravariceal pressure in man.

Jenkins SA, Baxter JN, Corbett WA, Shields R

The British journal of surgery1 Dec 1985Cited by 56 (Europe PMC)

PMID2867802DOI10.1002/bjs.1800721225PepBankPUB-02867802

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study10

10 results from studies that gave the peptide. 2 results from people.

01HumanNon-randomized trialEfficacy outcome
In cirrhosis with portal hypertension, SMS 201-995 reduced intravariceal pressure from 27.4 +/- 2.5 to 15.8 +/- 2.1 mmHg.
In plain wordsIn patients with cirrhosis and portal hypertension, SMS 201-995 reduced pressure inside varices.
Peptide
Octreotide
Outcome
DecreaseIntravariceal pressure
Study
n = 9
Outcome group
Blood pressure · Cardiovascular
Studied dose
50 microgramsAs given in this study (human).
Measurements
Intravariceal pressure
27.4 mmHg
before SMS 201-995, mean +/- 2.5
Intravariceal pressure
15.8 mmHg
after SMS 201-995, mean +/- 2.1
Source sentences
Summary
Administration of 50 micrograms SMS 201-995 reduced the intravariceal pressure from 27.4 +/- 2.5 to 15.8 +/- 2.1 mmHg in 9 patients with cirrhosis and portal hypertension.
Report a problemFND-0286780209
02HumanCase report or seriesEfficacy outcome
In a patient undergoing elective portacaval shunt, SMS 201-995 reduced portal pressure from 29 to 22 mmHg.
In plain wordsIn a patient undergoing shunt surgery, SMS 201-995 reduced portal pressure from 29 to 22 mmHg.
Peptide
Octreotide
Outcome
DecreasePortal pressure during shunt surgery
Study
n = 1
Outcome group
Blood pressure · Cardiovascular
Studied dose
50 microgramsAs given in this study (human).
Measurements
Portal pressure
29 mmHg
before SMS 201-995
Portal pressure
22 mmHg
after SMS 201-995
Source sentences
Summary
Administration of 50 micrograms SMS 201-995 also reduced portal pressure from 29 to 22 mmHg in a patient undergoing an elective portacaval shunt.
Report a problemFND-0286780210
03AnimalAnimal study (in vivo)Efficacy outcome
In pigs, SMS 201-995 infusion significantly reduced portal pressure.
In plain wordsIn pigs, SMS 201-995 infusion reduced portal pressure.
Peptide
Octreotide
Outcome
DecreasePortal pressure
Study
pign: not reported in source
Outcome group
Blood pressure · Cardiovascular
Studied dose
250 micrograms/h · infusionAs given in this study (pig).
Source sentences
Summary
An infusion of 250 micrograms/h SMS 201-995 significantly reduced portal pressure, portal venous flow and hepatic artery flow in the pig.
Report a problemFND-0286780201
04AnimalAnimal study (in vivo)Efficacy outcome
In pigs, SMS 201-995 infusion significantly reduced portal venous flow.
In plain wordsIn pigs, SMS 201-995 infusion reduced portal vein blood flow.
Peptide
Octreotide
Outcome
DecreasePortal venous flow
Study
pign: not reported in source
Outcome group
Hemodynamics · Cardiovascular
Studied dose
250 micrograms/h · infusionAs given in this study (pig).
Source sentences
Summary
An infusion of 250 micrograms/h SMS 201-995 significantly reduced portal pressure, portal venous flow and hepatic artery flow in the pig.
Report a problemFND-0286780202
05AnimalAnimal study (in vivo)Efficacy outcome
In pigs, SMS 201-995 infusion significantly reduced hepatic artery flow.
In plain wordsIn pigs, SMS 201-995 infusion reduced hepatic artery blood flow.
Peptide
Octreotide
Outcome
DecreaseHepatic artery flow
Study
pign: not reported in source
Outcome group
Hemodynamics · Cardiovascular
Studied dose
250 micrograms/h · infusionAs given in this study (pig).
Source sentences
Summary
An infusion of 250 micrograms/h SMS 201-995 significantly reduced portal pressure, portal venous flow and hepatic artery flow in the pig.
Report a problemFND-0286780203
06AnimalAnimal study (in vivo)Efficacy outcome
In pigs, SMS 201-995 reduced cardiac output alongside hepatic hemodynamic changes.
In plain wordsIn pigs, SMS 201-995 reduced blood output from the heart.
Peptide
Octreotide
Outcome
DecreaseCardiac output
Study
pign: not reported in source
Outcome group
Heart function · Cardiovascular
Studied dose
250 micrograms/h · infusionAs given in this study (pig).
Source sentences
Summary
These changes in hepatic haemodynamics were accompanied by a reduction in cardiac output, a reflex slowing of the heart and an increase in arterial blood pressure.
1 context sentence(design, population, supporting numbers)
Summary · context
An infusion of 250 micrograms/h SMS 201-995 significantly reduced portal pressure, portal venous flow and hepatic artery flow in the pig.
Report a problemFND-0286780204
07AnimalAnimal study (in vivo)Efficacy outcome
In pigs, SMS 201-995 produced reflex slowing of the heart alongside hepatic hemodynamic changes.
In plain wordsIn pigs, SMS 201-995 slowed the heart reflexively.
Peptide
Octreotide
Outcome
DecreaseHeart rate
Study
pign: not reported in source
Outcome group
Heart function · Cardiovascular
Studied dose
250 micrograms/h · infusionAs given in this study (pig).
Source sentences
Summary
These changes in hepatic haemodynamics were accompanied by a reduction in cardiac output, a reflex slowing of the heart and an increase in arterial blood pressure.
1 context sentence(design, population, supporting numbers)
Summary · context
An infusion of 250 micrograms/h SMS 201-995 significantly reduced portal pressure, portal venous flow and hepatic artery flow in the pig.
Report a problemFND-0286780205
08AnimalAnimal study (in vivo)Efficacy outcome
In pigs, SMS 201-995 increased arterial blood pressure alongside hepatic hemodynamic changes.
In plain wordsIn pigs, SMS 201-995 increased arterial blood pressure.
Peptide
Octreotide
Outcome
IncreaseArterial blood pressure
Study
pign: not reported in source
Outcome group
Blood pressure · Cardiovascular
Studied dose
250 micrograms/h · infusionAs given in this study (pig).
Source sentences
Summary
These changes in hepatic haemodynamics were accompanied by a reduction in cardiac output, a reflex slowing of the heart and an increase in arterial blood pressure.
1 context sentence(design, population, supporting numbers)
Summary · context
An infusion of 250 micrograms/h SMS 201-995 significantly reduced portal pressure, portal venous flow and hepatic artery flow in the pig.
Report a problemFND-0286780206
09AnimalAnimal study (in vivo)Efficacy outcome
In pigs, SMS 201-995 increased splanchnic vascular resistance.
In plain wordsIn pigs, SMS 201-995 increased resistance in abdominal blood vessels.
Peptide
Octreotide
Outcome
IncreaseSplanchnic vascular resistance
Study
pign: not reported in source
Outcome group
Hemodynamics · Cardiovascular
Studied dose
250 micrograms/h · infusionAs given in this study (pig).
Source sentences
Summary
Splanchnic vascular resistance was increased following SMS 201-995 administration but hepatic vascular resistance remained unchanged.
1 context sentence(design, population, supporting numbers)
Summary · context
The effects of a somatostatin analogue, SMS 201-995, on hepatic haemodynamics in the pig and on intravariceal pressure in man were studied.
Report a problemFND-0286780207
10AnimalAnimal study (in vivo)Efficacy outcome
In pigs, hepatic vascular resistance remained unchanged after SMS 201-995.
In plain wordsIn pigs, liver blood vessel resistance remained unchanged after SMS 201-995.
Peptide
Octreotide
Outcome
No significant changeHepatic vascular resistance
Study
pign: not reported in source
Outcome group
Hemodynamics · Cardiovascular
Studied dose
250 micrograms/h · infusionAs given in this study (pig).
Source sentences
Summary
Splanchnic vascular resistance was increased following SMS 201-995 administration but hepatic vascular resistance remained unchanged.
1 context sentence(design, population, supporting numbers)
Summary · context
The effects of a somatostatin analogue, SMS 201-995, on hepatic haemodynamics in the pig and on intravariceal pressure in man were studied.
Report a problemFND-0286780208

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:36 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.